HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Status:
Terminated
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
Phase IV, open-label, randomized, two-arm, multi-center study in patients with metastatic
melanoma who are treatment naïve or have previously received a single non-immunologic
therapy.
Treatment Arm 1: Patients will receive two courses (four cycles) of High Dose Interleukin-2
(HD IL-2) followed by one course (four doses) of ipilimumab.
Treatment Arm 2: Patients will receive one course (four doses) of ipilimumab followed by two
courses (four cycles) of HD IL-2.
Phase:
Phase 4
Details
Lead Sponsor:
Clinigen, Inc. Prometheus Laboratories
Collaborators:
Johns Hopkins University M.D. Anderson Cancer Center